Disease-modifying therapies in short bowel syndrome

Brune de Dreuille; Francisca Joly

doi:10.1016/j.coph.2022.102240

Disease-modifying therapies in short bowel syndrome

Curr Opin Pharmacol. 2022 Aug:65:102240. doi: 10.1016/j.coph.2022.102240. Epub 2022 May 23.

Authors

Brune de Dreuille¹, Francisca Joly²

Affiliations

¹ Department of Gastroenterology and Nutritional Support, Center for Intestinal Failure, Reference Centre of Rare Disease MarDI, AP-HP Beaujon Hospital, University of Paris Inserm UMR 1149, Paris, France.
² Department of Gastroenterology and Nutritional Support, Center for Intestinal Failure, Reference Centre of Rare Disease MarDI, AP-HP Beaujon Hospital, University of Paris Inserm UMR 1149, Paris, France. Electronic address: francisca.joly@aphp.fr.

PMID: 35617915
DOI: 10.1016/j.coph.2022.102240

Abstract

Short bowel syndrome (SBS) is the main cause of chronic intestinal failure (IF), defined as 'the reduction of gut function below the minimum necessary for the absorption of macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth'. SBS is a rare disease requiring a multidisciplinary approach in specialized IF units. The aim of this review was to discuss the current pharmacological management of SBS-associated IF, since emerging treatments are currently modifying the natural evolution of these patients. Enterohormone therapy has become the first-choice treatment and may decrease the need for parenteral support and improve patients' quality of life.

Publication types

Review

MeSH terms

Humans
Intestinal Absorption
Intestinal Diseases* / therapy
Parenteral Nutrition
Quality of Life
Short Bowel Syndrome* / drug therapy